

Survey questionnaire

Treatment of chronic hepatitis C infection in children and adolescents

Values and preferences survey

Survey

You are being invited to participate in an online survey about treatment for children and adolescents living with chronic hepatitis C virus (HCV) infection. This survey is being conducted to understand healthcare workers' preferences about which children to treat and what direct acting antiviral (DAA) regimens to use. Results from this survey will be used to update World Health Organization's (WHO) guideline recommendations on treatment of children (those < 12 years old) and adolescents (between 12 and 18 years old).

The survey comprises 17 questions and should take no more than 15 minutes to complete.

Survey information is anonymised, and no personal identifiers will be associated with your responses or any final reports of these data. Your participation is entirely voluntary. Further details, including information about data protection, are available in the participant information sheet that you can download [here](#).

For further information, please contact fariahah.malik.18@ucl.ac.uk

We very much appreciate your time in completing this important survey.

Survey Questions

Section A Information about you and your practice	
1. Please type the country for which you are most qualified to discuss current practices for HCV treatment (in most cases, will be your country of residence)	Open ended
2. What best describes your role? Please select one	Dropdown menu with the following options: <input type="checkbox"/> Hepatologist/ Gastroenterologist <input type="checkbox"/> Infectious disease specialist <input type="checkbox"/> Paediatrician/ paediatric infectious diseases/paediatric hepatologist <input type="checkbox"/> General Physician/ Family physician <input type="checkbox"/> Nurse <input type="checkbox"/> Other (please specify)
3. At what type of facility do you practice? Please select one	<input type="checkbox"/> Tertiary (e.g. national, regional or university hospital) <input type="checkbox"/> Secondary (e.g. district or county hospital) <input type="checkbox"/> Primary (e.g. community hospital or rural centre) <input type="checkbox"/> Private clinic <input type="checkbox"/> NGO clinic
4. How long have you been working in the field of viral hepatitis?	<input type="checkbox"/> Less than 1 year <input type="checkbox"/> 1-2 years <input type="checkbox"/> 3-5 years <input type="checkbox"/> 5-10 years <input type="checkbox"/> More than 10 years
5. Approximately how many children and adolescents with chronic HCV have you cared for in your practice or facility over the last three years? Please provide estimates	Children (<12 years) Adolescents (12-18 years) [SKIP - If both are zero skip to Q6]

5a. Approximately how many children and adolescents with HCV have you treated **over the last three years** in your practice/facility, in the following different age groups (outside of clinical trials)?

Please check all that apply

	None	1 – 10	11 – 20	21 – 50	More than 50
0 to < three years old					
3 to < 6 years old					
6 to < 12 years old					
12 to <18 years					

5b. **Over the last three years**, what drug regimens have you used to treat children and adolescents with HCV in your practice/facility, in the following different age groups?

Please check all that apply

	0 to < three years old	3 to < 6 years old	6 to < 12 years old	12 to <18 years
Interferon or Pegylated interferon + ribavirin				
Sofosbuvir +interferon				
Sofosbuvir + ribavirin				
Sofosbuvir/daclatasvir				
Sofosbuvir/ledipasvir				
Sofosbuvir/velpatasvir				
Sofosbuvir/velpatasvir/voxilaprevir				
Glecaprevir/pibrentasvir				

Section B Information about current HCV treatment for children and adolescent in your practice/facility and country

6. Are any drug regimens currently available in **your practice/facility** for treatment of HCV infection in children and adolescents?

- ☐ Yes
☐ No [Skip to Q7]

6a. Which of the following drug regimens are **currently available in your practice/facility** * for treatment of HCV infection in adolescents and children, in the following different age groups?
 *outside of clinical trials

	0 to < three years old	3 to < 6 years old	6 to < 12 years old	12 to <18 years
Interferon or Pegylated interferon + ribavirin				
Sofosbuvir + interferon				
Sofosbuvir + ribavirin				

	Sofosbuvir/daclatasvir					
	Sofosbuvir/ledipasvir					
	Sofosbuvir/velpatasvir					
	Sofosbuvir/velpatasvir/voxilaprevir					
	Glecaprevir/pibrentasvir					

7Are any drug regimens currently registered and approved in your country for treatment of HCV infection in children and adolescents?	<input type="checkbox"/> Yes <input type="checkbox"/> No [Skip to Q8] <input type="checkbox"/> Don't know [Skip to Q8]
---------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------

7a.Which of the following drug regimens are currently **registered and approved** for treatment of HCV infection in children and adolescents **in your country**, in the following different age groups?

	0 to < three years old	3 to < 6 years old	6 to < 12 years old	12 to <18 years
Interferon or Pegylated interferon + ribavirin				
Sofosbuvir + interferon				
Sofosbuvir + ribavirin				
Sofosbuvir/daclatasvir				
Sofosbuvir/ledipasvir				
Sofosbuvir/velpatasvir				
Sofosbuvir/velpatasvir/voxilaprevir				
Glecaprevir/pibrentasvir				

8.What is the main source of funding for paediatric hepatitis treatment at your practice/facility?	Select one: <input type="checkbox"/> Patients (i.e., self-funded) <input type="checkbox"/> Government (public sector) <input type="checkbox"/> Private insurance <input type="checkbox"/> NGO <input type="checkbox"/> Other (please specify below)
-----------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Section C Preferences for future HCV treatment and DAA regimens

9. How important are the following outcomes/concerns when you are considering whether to treat children and adolescents?

	Not at all important	Low importance	Neutral	Very important	Extremely important
SVR12 (cure)					
Measure of liver disease (e.g. biopsy, non-invasive liver fibrosis assessments)					
Presence and severity of symptoms					
Measures of psychological well being					
Measures of physical function					
Educational attainment					
Long-term adverse effects					

Prevention of transmission to other persons					
Prevention of stigmatisation of infected children					

10a. If DAAs were available for treatment of HCV infection in children and adolescents in your practice/facility, how likely would you be to treat children in the following age groups:

	Extremely unlikely	Unlikely	Neutral	Likely	Extremely likely
0 to < three years old					
3 to < 6 years old					
6 to < 12 years old					
12 to <18 years					

10b. Please specify reasons for your preferences for not treating a particular age group

Open-ended

11a. If DAAs were available for treatment of HCV infection in children and adolescents in your practice/facility, which DAA regimens would you prefer to use in the following age groups:

	0 to < three years old	3 to < 6 years old	6 to < 12 years old	12 to <18 years
Sofosbuvir + interferon				
Sofosbuvir + ribavirin				
Sofosbuvir/daclatasvir				
Sofosbuvir/ledipasvir				
Sofosbuvir/velpatasvir				
Sofosbuvir/velpatasvir/voxilaprevir				
Glecaprevir/pibrentasvir				

11b. Please specify reasons for your preferences

Open-ended

12. Which children would you prioritise for treatment with DAAs?

Open-ended

13. Which children would you not wish to treat with DAAs?

Open-ended

14. In your opinion, what is the threshold age at which treatment of children with HCV should be recommended in treatment guidelines?

Please select one

- ☐ All age groups should be treated
- ☐ three years and above
- ☐ 6 years and above
- ☐ 12 years and above
- ☐ Other, please specify

Section D Barriers and solutions to promoting access to HCV treatment for children and adolescents	
<p>15.What barriers do you face in your practice/facility in treating children and adolescents with HCV infection?</p> <p>Select all that apply</p>	<p><input type="checkbox"/> Lack of national policies and guidelines</p> <p><input type="checkbox"/> DAAs are not available</p> <p><input type="checkbox"/> DAAs are available but not registered for use in children and adolescents</p> <p><input type="checkbox"/> DAAs are available but not free (patients have to pay to receive treatment)</p> <p><input type="checkbox"/> DAAs are available but paediatric formulations are not available</p> <p><input type="checkbox"/> Lack of awareness among health professionals</p> <p><input type="checkbox"/> Lack of awareness among patients</p> <p><input type="checkbox"/> Fear/misconceptions about the treatment</p> <p><input type="checkbox"/> Others (please specify)</p>
<p>16.What are your suggestions to facilitate access and uptake of HCV testing and treatment for children and adolescents?</p>	<p>Open ended questions</p>
<p>17. Is there anything else you would like to tell us about promoting access to HCV testing and treatment of children and adolescents in your country?</p>	
<p>If you are interested in collaborating in sharing of anonymized individual patient data to future studies, please enter your name and email address</p>	<p>Respondent name</p> <p>Respondent email</p>

By clicking the 'Submit' button below, you are consenting to participate in this study, as it is described in the participant information sheet, which you can download [here](#).

We very much appreciate your time in completing this survey!